An obesity drug from Boehringer Ingelheim and Zealand Pharma helped patients with diabetes lose up to 13.1% of their body weight, a result that Bloomberg News describes as disappointing. The pharmaceutical company has positioned the medicine as a treatment that allows patients to shed fat while preserving muscle mass. However, without a distinct advantage over existing treatments, the drug faces a challenging path in a market already dominated by Eli Lilly and Novo.
Boehringer Ingelheim disputed the notion that its product will serve only a niche audience. The company stated that upcoming studies focused on heart and liver health will more clearly demonstrate the medication's potential.
Meanwhile, the upcoming midterm elections are poised to bring significant changes to key Senate committees that influence health care policy, according to STAT. Both the Senate Finance Committee and the Committee on Health, Education, Labor, and Pensions, or HELP, could undergo major shifts. If Democrats secure control of the Senate, they would assume leadership of these panels. However, changes in the Republican membership are also expected to affect the committees' directions.
Five or more of the 14 Republicans on the Senate Finance Committee are set to leave their seats. The outlook for the HELP Committee is even harder to predict due to the departure of chairman Bill Cassidy.
In a separate development, Novartis signed a licensing deal with Chinese biotech company Abogen worth approximately $7.8 billion to advance RNA-based therapy, Reuters reports. Under the agreement, Novartis will gain exclusive rights to Abogen's experimental drug, ABO2203. The deal also includes options for Novartis to license other therapies and additional experimental medicines developed using Abogen's RNA technology platform.
The experimental drug is designed to treat autoimmune diseases by targeting B cells. These are a type of immune cell that contributes to disease in conditions such as lupus and rheumatoid arthritis.